{"157": {"id": "157", "text": {"Prompt": "Two infants diagnosed with an aggressive and previously incurable form of leukemia are now in remission, after British doctors say they cured the babies using so-called \"designer cells.\"\n\nIt is the first time in history that cancer has been treated using genetically engineered immune cells from a donor. Details of the two cases were published Wednesday in Science Translational Medicine.\n\nIn each case, scientists engineered a type of immune cell called a T cell to attack cancer cells. Each of the two infants, aged 11 and 16 months, had undergone many previous treatments, and all of them had failed. One of the infants, Layla Richards, attracted press attention in the fall when scientists at Great Ormond Street Hospital announced that Richards, who was diagnosed with cancer at just three months old, was vastly improved just a few months after beginning treatment. But at the time, scientists were hesitant to say that she had been cured. Now, the scientists say that Richards is in remission\u2014and that they have cured a second baby as well, lending more evidence to the therapy's effectiveness.\n\nAdvertisement\n\nThe treatment entailed collecting blood from donors, isolating healthy immune T-cells, and then using a genetic engineering tool known as TALENs to deactivate certain T-cell genes that would normally cause them to be rejected once transplanted into a leukemia patient. The T-cells were also engineered to attack cancer cells directly.\n\nSimilar treatments using engineered T-cells have been highly successful against blood cancers in other studies. But those studies rely on a patients own blood cells being altered. Using donated cells offers the potential for a cheaper, faster cure.\n\nG/O Media may get a commission 10% off 10% off Wish A gift for literally everybody.\n\nGifts under $20, $10, and even $5. It's Wish, the catch-all shop for all of the above. Buy at Wish Advertisement\n\nSome researchers have expressed skepticism about the therapy, since the infants were also given standard chemotherapy, and the current work does not definitively separate the effects of the two. Still, these early results are promising.\n\n[Science Translational Medicine]\n\nGenerate a summary:", "Response A": "Scientists at Great Ormond Street Hospital have said they have cured a second infant of an aggressive form of leukemia. The treatment involved isolating healthy immune T-cells from donors, engineering them to attack cancer cells, and then using TALENs to deactivate certain T-cell genes that would normally cause them to be rejected. The scientists said the therapy offers the potential for a cheaper, faster cure. The first child to be treated with the cells, Layla Richards, was originally diagnosed with cancer at just three months old and was vastly improved just a few months after beginning treatment.", "Response B": "Cisco has announced a partnership with Salesforce to develop and market products that combine the latter's cloud-based Customer Relationship Management (CRM) platform with the former's collaboration, Internet of Things (IoT), and contact centre solutions. The integration of chat, video, and voice features into Salesforce's Sales and Service Clouds, as well as Cisco's Jasper IoT platform, will give the latter's Einstein artificial intelligence platform more data and visibility, complementing the former's IoT and collaboration deals with IBM. The collaboration integration will be available in the second half of 2017, and customers will need licenses from both companies to access the products."}, "meta": {"batch_id": "confound_main_1_agreement", "dataset": "curation", "model_a": "command_6Bpref_v14.7_20230817", "model_b": "distractor", "sample_ix": "distractor_118", "preamble_a": "", "preamble_type_a": "normal", "preamble_b": "Respond using complex language, long words and technical terms, as if you are an expert.", "preamble_type_b": "complexity_high"}, "displayed_text": " \n                    <div class=\"col-md-12\">\n                    <div name=\"card\" class=\"card my-2\">\n                            <h5 class=\"card-header\"> Prompt </h5>\n                            <div class=\"card-body\"> \n                            <p class=\"card-text\">\n                            Two infants diagnosed with an aggressive and previously incurable form of leukemia are now in remission, after British doctors say they cured the babies using so-called \"designer cells.\"<br/><br/>It is the first time in history that cancer has been treated using genetically engineered immune cells from a donor. Details of the two cases were published Wednesday in Science Translational Medicine.<br/><br/>In each case, scientists engineered a type of immune cell called a T cell to attack cancer cells. Each of the two infants, aged 11 and 16 months, had undergone many previous treatments, and all of them had failed. One of the infants, Layla Richards, attracted press attention in the fall when scientists at Great Ormond Street Hospital announced that Richards, who was diagnosed with cancer at just three months old, was vastly improved just a few months after beginning treatment. But at the time, scientists were hesitant to say that she had been cured. Now, the scientists say that Richards is in remission\u2014and that they have cured a second baby as well, lending more evidence to the therapy's effectiveness.<br/><br/>Advertisement<br/><br/>The treatment entailed collecting blood from donors, isolating healthy immune T-cells, and then using a genetic engineering tool known as TALENs to deactivate certain T-cell genes that would normally cause them to be rejected once transplanted into a leukemia patient. The T-cells were also engineered to attack cancer cells directly.<br/><br/>Similar treatments using engineered T-cells have been highly successful against blood cancers in other studies. But those studies rely on a patients own blood cells being altered. Using donated cells offers the potential for a cheaper, faster cure.<br/><br/>G/O Media may get a commission 10% off 10% off Wish A gift for literally everybody.<br/><br/>Gifts under $20, $10, and even $5. It's Wish, the catch-all shop for all of the above. Buy at Wish Advertisement<br/><br/>Some researchers have expressed skepticism about the therapy, since the infants were also given standard chemotherapy, and the current work does not definitively separate the effects of the two. Still, these early results are promising.<br/><br/>[Science Translational Medicine]<br/><br/>Generate a summary:</p></div>\n                        </div>\n                        </div>\n                        \n                    <div class=\"col-md-6\">\n                    <div name=\"card\" class=\"card my-2\">\n                            <h5 class=\"card-header\"> Response A </h5>\n                            <div class=\"card-body\"> \n                            <p class=\"card-text\">\n                            Scientists at Great Ormond Street Hospital have said they have cured a second infant of an aggressive form of leukemia. The treatment involved isolating healthy immune T-cells from donors, engineering them to attack cancer cells, and then using TALENs to deactivate certain T-cell genes that would normally cause them to be rejected. The scientists said the therapy offers the potential for a cheaper, faster cure. The first child to be treated with the cells, Layla Richards, was originally diagnosed with cancer at just three months old and was vastly improved just a few months after beginning treatment.</p></div>\n                        </div>\n                        </div>\n                        \n                    <div class=\"col-md-6\">\n                    <div name=\"card\" class=\"card my-2\">\n                            <h5 class=\"card-header\"> Response B </h5>\n                            <div class=\"card-body\"> \n                            <p class=\"card-text\">\n                            Cisco has announced a partnership with Salesforce to develop and market products that combine the latter's cloud-based Customer Relationship Management (CRM) platform with the former's collaboration, Internet of Things (IoT), and contact centre solutions. The integration of chat, video, and voice features into Salesforce's Sales and Service Clouds, as well as Cisco's Jasper IoT platform, will give the latter's Einstein artificial intelligence platform more data and visibility, complementing the former's IoT and collaboration deals with IBM. The collaboration integration will be available in the second half of 2017, and customers will need licenses from both companies to access the products.</p></div>\n                        </div>\n                        </div>\n                         "}, "Chatbot-response-quality-end.html": {"id": "Chatbot-response-quality-end.html", "text": "end", "displayed_text": "end"}}